4.8 Article

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR

Journal

NATURE MEDICINE
Volume 21, Issue 7, Pages 741-+

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nm.3863

Keywords

-

Funding

  1. European Community's Seventh Framework Programme FP7 [PIAPP-GA-2009-230614]
  2. Worldwide Cancer Research grant [15-0354]
  3. European Research Council [268626-EPINORC]
  4. Ministerio de Ciencia e Innovacion [SAF2011-22803, FIS PI13-01339]
  5. CRUK Manchester Institute [C5759/A12328]
  6. Wellcome Trust [100282/Z/12/Z]
  7. Cellex Foundation
  8. Health Department of the Catalan Government Generalitat de Catalunya [2005-SGR00727, 2014-SGR 633]
  9. Science Department of the Catalan Government Generalitat de Catalunya [2005-SGR00727, 2014-SGR 633]
  10. Formacion de Profesorado Universitario fellowship from the Spanish Ministry of Education
  11. Cancer Research UK [19279, 17240] Funding Source: researchfish
  12. Worldwide Cancer Research [15-0354] Funding Source: researchfish
  13. ICREA Funding Source: Custom

Ask authors/readers for more resources

Metastasis is responsible for most cancer-related deaths, and, among common tumor types, melanoma is one with great potential to metastasize. Here we study the contribution of epigenetic changes to the dissemination process by analyzing the changes that occur at the DNA methylation level between primary cancer cells and metastases. We found a hypomethylation event that reactivates a cryptic transcript of the Rab GTPase activating protein TBC1D16 (TBC1D16-47 kDa; referred to hereafter as TBC1D16-47KD) to be a characteristic feature of the metastatic cascade. This short isoform of TBC1D16 exacerbates melanoma growth and metastasis both in vitro and in vivo. By combining immunoprecipitation and mass spectrometry, we identified RAB5C as a new TBC1D16 target and showed that it regulates EGFR in melanoma cells. We also found that epigenetic reactivation of TBC1D16-47KD is associated with poor clinical outcome in melanoma, while conferring greater sensitivity to BRAF and MEK inhibitors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available